v3.26.1
Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenues $ 398 $ 381
Less:    
Cost of revenues 134 106
R&D costs 2,319 2,515
G&A costs 2,720 2,941
Net loss (4,736) (5,011)
Reportable Segment [Member]    
Segment Reporting Information [Line Items]    
Revenues [1] 398 381
Less:    
Cost of revenues 134 106
R&D costs [2] 572 485
G&A costs [3] 1,685 1,400
Personnel costs [4] 2,438 3,023
Other segment items [5] 305 378
Net loss $ (4,736) $ (5,011)
[1] (1) Includes Contract Manufacturing and Clinical Trial revenue
[2]

(2) Includes Clinical Development, Research & Discovery, CMC

[3]

(3) Includes Executive, Finance, Legal, Business Operations

[4]

(4) Includes compensation, benefits and equity-based compensation

[5] (5) Includes depreciation and amortization, (interest income) and other specific charges